

1. (Twice Amended)

A method of preventing or treating a nitric oxide-mediated disease or condition in a mammalian subject comprising administering to the mammal a disease or condition prevention or treatment effective amount of a peptide, oligopeptide, or protein that acts as a substrate for or an inhibitor of nitric oxide synthase, whereby the tertiary structure of the peptide, oligopeptide, or protein inhibitor is such that one or more arginine groups are available to the nitric oxide synthase, said peptide, oligopeptide or protein being selected from the group consisting of L-Arginine, Poly-Arginine, BK, Des-Arg1-BK, Des-Arg9-BK, BK fragment 1-7, BK fragment 2-7, [Lys1]-BK, Lys-BK, Ile-Ser-BK, and Met-Lys-BK.

+ Kinin

Kallidin (Arg9)
B2

Please cancel claims 3, 5-6, 9-11, 13, and 15-16.

Please add new claims 17-19:

17. (New)

The method of claim 1 wherein the disease or condition relates to a cardiovascular, gastrointestinal, or bronchial disorder.

18. (New)

The method of claim 17 wherein the disease or condition is selected from the group consisting of ischemic stroke, diabetes, systemic hypotension, multiple sclerosis, Huntington's disease, Parkinson's disease, and Alzheimer's disease.

low blood pressure
Cardio dilation
BK is VASODILATOR
BK induces hypotension

(19. (New))

A method of preventing or treating a nitric oxide-mediated disease or condition in a mammalian subject consisting essentially of administering to the mammal a disease or condition prevention or treatment effective amount of a peptide, oligopeptide, or protein that acts as a substrate for or an inhibitor of nitric oxide synthase, whereby the tertiary structure of the peptide, oligopeptide, or protein inhibitor is such that one or more arginine groups are available to the nitric oxide synthase, said peptide, oligopeptide or protein being selected from the group consisting of L-Arginine, Poly-Arginine, BK, Des-Arg1-BK, Des-Arg9-BK, BK fragment 1-7, BK fragment 2-7, [Lys1]-BK, Lys-BK, Ile-Ser-BK, and Met-Lys-BK.]

C2